Blocking insulin-like growth factor 1 receptor using specific antibodies can prolong the therapeutic effects of botulinum toxin-A for continued benefits

Botulinum toxin-A (BTX) therapy is often used in cosmetology and to treat neuromuscular conditions. However, its therapeutic effects weaken as the neuromuscular junction heals, necessitating repeated injections. Now, Shimane University researchers have shown that antibodies against the insulin-like growth factor 1 receptor on cells can hinder neuromuscular junction recovery after BTX injection, thereby prolonging its therapeutic effects. In clinical settings, this strategy could reduce the number of treatment sessions required by patients to their advantage.

View More